Peptide Protocol IQ

Evidence grading scale

Two independent axes, applied per claim. A single “good or bad” score would be easier to read and considerably less honest.

Axis one

Evidence level

AStrong

Multiple high-quality human trials, or strong systematic-review or meta-analytic evidence.

BModerate

Human controlled evidence exists, but replication or sample size is limited.

CPreliminary

Small human studies, observational evidence, or early-phase clinical work.

DPreclinical

Predominantly animal or in-vitro evidence. No adequate human outcome data.

EMechanistic

Biological plausibility or mechanistic reasoning without adequate outcome evidence.

XInsufficient / conflicting

Evidence is absent, irreconcilable, or too weak to support any directional statement.

Axis two

Confidence

How settled the finding is, reported separately from how strong the underlying design was. A single small but well-conducted trial and a large trial with contested methodology can occupy the same evidence level while differing sharply in confidence.

High confidence

Replicated, consistent, and unlikely to change materially with additional evidence of similar quality.

Moderate confidence

Reasonably consistent, but replication is limited or the evidence comes from a narrow set of sources.

Low confidence

Sparse, inconsistent, or concentrated within a small number of research groups.

Very low confidence

Effectively unreplicated, or originating from a single programme with limited independent scrutiny.

Interactions

Severity scoring

Severity describes how consequential an interaction would be if real. It is reported separately from certainty, because a hypothetical serious concern and a well-established mild one are different things.

0No documented signal

No interaction meeting our evidence criteria is documented. This is not a statement of safety.

1Informational overlap

A shared pathway or overlapping domain worth knowing about, without a specific concern attached.

2Research caution

A concern warranting attention and discussion with a clinician.

3Significant research concern

A significant concern, typically supported by approved labelling or by clear mechanistic redundancy.

4Do-not-combine flag

Flagged in the platform as a combination we will not present as researchable together.

Interactions

Classification types

Documented interaction

Reported in human evidence or in authoritative product labelling.

Potential interaction

Plausible and partially supported, but not established in dedicated study.

Labeled contraindication

An approved product's labelling states the combination should not be used.

Mechanistic overlap

The compounds act on the same pathway. Reasoning-based, not an observed interaction.

No qualifying signal identified

Nothing meeting our criteria was identified. Usually this means nobody has looked.

Inadequately studied

The question has been asked but not answered by adequate evidence.

Conflicting evidence

Evidence points in more than one direction and cannot currently be reconciled.

An X is not a failing grade

Grade X means the evidence is absent, conflicting, or too weak to support a directional statement. It says something about the state of the literature, not about the compound. Some of the most scientifically interesting compounds in this catalogue carry X grades, precisely because nobody has yet done the work that would settle the question.